Our previous studies indicated that tau was expressed in a higher number of metastatic than primary ovarian cancer specimens, and stimulation with three-dimensional collagen type I, a model of the extracellular matrix at metastatic sites in the peritoneal cavity [79,80], resulted in upregulation of tau and increased paclitaxel resistance that was reversed by the siRNA-driven tau downregulation [41]. Here, MAPT is linked to ovarian carcinoma.